ClinicalTrials.gg
RecruitingNCT07567170BF-ACTUpdated May 5, 2026

Satisfaction of Specific Modes Related to Physical Activity in People Living With Type 1 Diabetes and Using an Hybrid Closed-loop System

An interventional study of Questionnar in Diabetes, sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
900
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 352 studies in Diabetes Mellitus with a site in France — 47 open to participants now, 53 under way, 3 of them phase 3. Diabetes Mellitus · France.

Planned enrollment
38th of 242
900 · median 187
Started
2026
with 10 others
No phase
100 of 352
22 open now
Primary completion
2026-08
later than 20 of 51 live
Registered
346th of 352
by date

Among the 352 studies in Diabetes Mellitus with a site in France, this one is the 38th largest by planned enrollment of the 242 interventional ones that give a count, is one of 11 that started in 2026, is one of 100 with no phase, reaches primary completion later than 20 of the 51 other live ones, and was the 346th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

47 of the 352 studies in Diabetes Mellitus with a site in France are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 352 studies in Diabetes Mellitus with a site in France, or all of them as a file.
02

Study summary

The BF-ACT study is a single-center, non-interventional (RIPH3) descriptive study conducted at CHU Grenoble Alpes. It aims to evaluate the satisfaction of adults with type 1 diabetes using closed-loop insulin delivery systems, specifically regarding the "physical activity mode" designed to adapt insulin delivery during exercise.

Although physical activity is essential for managing type 1 diabetes, it remains challenging due to the risk of hypoglycemia. Closed-loop systems have improved glucose control, but their effectiveness during exercise depends on multiple factors, and their real-life use can be complex. Currently, little is known about patient satisfaction and experience with these specific modes.

The study will collect data through a self-administered questionnaire, distributed to eligible patients (≥18 years old, with type 1 diabetes, using a closed-loop system for at least 4 months). The primary outcome is the satisfaction score based on the questionnaire. Secondary objectives include describing physical activity perception, usage of the activity mode, and comparing users versus non-users.

Approximately up to 900 patients may be included over a 4-month recruitment period. Clinical and glucose monitoring data will also be collected from medical records. The results are expected to improve patient education, device usability, and support for physical activity in people living with type 1 diabetes.

03

Conditions studied

  • Diabetes

Keywords

  • Closed-loop
  • automated insulin delivery
  • physical activity
  • PROMs
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patient living with type 1 diabetes
  • Patient using a closed-loop system for at least 4 months
  • Patient followed by a diabetologist in our center

Exclusion criteria

Exclusion criteria

  • People opposed to the research
  • People protected by the law
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Other
    Only 1 arm = patient treated with AID systems

    Other: Questionnar

Interventions

  • OtherQuestionnar

    Administration of 1 questionnar to investigate the satisfaction with the physical activity mode of closed-loop systems among people living with type 1 diabetes.

06

What researchers measure

Primary outcomes

  1. Satisfaction score

    Part C, D and E of the questionnar

    Time frame: Baseline

Secondary outcomes

  1. Describe the perception of physical activity within the study population

    Part A of the questionnar

    Time frame: Baseline

  2. Describe the proportion of individuals using the physical activity mode in our study

    Part B of the questionnar

    Time frame: Baseline

  3. Describe satisfaction with the mode in relation to the physical activities performed by patients

    Part F of the questionnar

    Time frame: Baseline

  4. Describe overall satisfaction with the "physical activity" mode

    Part G of the questionnar

    Time frame: Baseline

  5. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: HbA1c (%)

    Time frame: Baseline

  6. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: Type of closed-loop system

    Time frame: Baseline

  7. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: Duration of use of the closed-loop system

    Time frame: Baseline

  8. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: Time spent in closed-loop mode

    Time frame: Baseline

  9. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: Duration of type 1 diabetes

    Time frame: Baseline

  10. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: Age

    Time frame: Baseline

  11. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: Sex

    Time frame: Baseline

  12. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: Body Mass Index (BMI)

    Time frame: Baseline

  13. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: CGM data over the 15 days prior to questionnaire completion: * Time in Range (TIR) 70-180 mg/dL * Time in Tight Range (TITR) 70-140 mg/dL * Time Above Range (TAR) \> 180 mg/dL and \> 250 mg/dL * Time Below Range (TBR) \< 70 mg/dL and \< 54 mg/dL

    Time frame: Baseline

  14. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: CGM data over the 15 days prior to questionnaire completion: \- Mean glucose (mg/dL)

    Time frame: Baseline

  15. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: CGM data over the 15 days prior to questionnaire completion: \- Glucose Management Index (GMI)

    Time frame: Baseline

  16. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: CGM data over the 15 days prior to questionnaire completion: \- Coefficient of Variation (CV, in %)

    Time frame: Baseline

  17. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: CGM data over the 15 days prior to questionnaire completion: \- Glycemia Risk Index (GRI)

    Time frame: Baseline

  18. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: CGM data over the 15 days prior to questionnaire completion: \- Total daily insulin dose (IU/day)

    Time frame: Baseline

  19. Compare populations who use the physical activity mode with those who do not use it

    Comparison based on several parameters to describe the two populations at the time of questionnaire completion: CGM data over the 15 days prior to questionnaire completion: \- Percentage of use of the physical activity mode

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2026, 4 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 4 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
May 5, 2026
StartActual
Apr 21, 2026
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07567170
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Apr 21, 2026
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Quentin Perrier, PharmD, phD
Contact
qperrier@chu-grenoble.fr
+33 4 76 76 55 16

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion